基于真实世界的舒血宁注射液治疗脑梗死患者临床用药特征分析

Analysis of clinical use of Shuxuening injection in treatment of cerebral infarction based on real world

为了解使用舒血宁注射液的脑梗死患者一般情况、临床用药特点及合并用药特征,采用频数分析和关联规则分析方法,对来自全国20家三甲综合医院信息系统的6 053例脑梗死患者信息进行分析。使用舒血宁注射液脑梗死患者中,患者平均年龄67.96岁,其中46-80岁的患者共4 589例,占83.94%;舒血宁注射液用法主要为静脉用药,单次给药剂量以15-20 mL为最多,占69.7%;用药疗程一般1-14 d,占89.25%;主要单种联合用药有阿司匹林肠溶片（支持度48.508%）、马来酸桂哌齐特注射液（支持度22.073%）、阿托伐他汀钙片（支持度18.873%）等;2种联合用药常用组合主要为马来酸桂哌齐特注射液＋阿司匹林肠溶片（支持度8.178%）,尼麦角林胶囊＋阿司匹林肠溶片（支持度7.63%）等。舒血宁注射液治疗脑梗死患者时中老年人为最多,并常与抗血小板聚集药、改善脑循环药物等具有相似药理作用的化学药物一起合并使用,临床用药符合脑梗死治疗指南,部分患者存在超说明书推荐剂量使用情况,临床医师应注意用药规范。

To know the characteristics of Shuxuening injection used on cerebral infarction patients in clinical practice,6 053 cases of Hospital information system（HIS） data from 20 hospitals were analyzed.Using the basic description method and association rules to analysis the data.By analysis the data we found that the average age of cerebral infarction patients who used Shuxuening injection is 67.96,83.94%of patients were aged 46-80.The injection is administered intravenously,with most patients receiving a dosage of 15-20 mL per dose for between 1 and 14 days.It is always combined with aspirin（48.508%）,cinepazide maleate injection（22.073%）,atorvastatin calcium tablets（18.873%） in clinical practice.When it comes to two drug combinations,it always combined with cinepazide maleate injection and aspirin（8.178%）,nicergoline capsules and aspirin（7.63%）.Therefore,based on existing data,we give the conclusion that for the treatment of cerebral infarction Shuxuening injection is mainly used for older patients,and is often combination with similar pharmacological effects chemical drugs,which is complied with the guidelines.However,the wrong dose is still exist,doctors should realize the hiding risk.